Buckingham Strategic Wealth’s Theriva Biologics TOVX Stock Holding History

Buckingham Strategic Wealth’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-70	Closed	-$5K	–	629
2021 Q4	$5K	Buy	+70	New	+$6.6K	﹤0.01%	599

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Buckingham Strategic Wealth's TOVX Position: Q1 2022 in Review

Buckingham Strategic Wealth sold out of Theriva Biologics (TOVX) in Q1 2022, closing a stake of 70 shares — an estimated $5K sold.

Buckingham Strategic Wealth first reported a position in TOVX in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 32 funds tracked by Wall St. Rank hold TOVX as of Q1 2022.

Buckingham Strategic Wealth reported no remaining Theriva Biologics position as of Q1 2022 after selling out during the quarter.
Buckingham Strategic Wealth sold 70 Theriva Biologics shares in Q1 2022, an estimated $5K.
Buckingham Strategic Wealth first reported a position in Theriva Biologics in Q4 2021 and held it in 1 quarter.
Buckingham Strategic Wealth's Theriva Biologics position peaked at $5K in Q4 2021.
32 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2022.

Based on Buckingham Strategic Wealth's 13F filing for Q1 2022, filed 10 May 2022.